S&P 500

5.643,50

0,22%

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

AZN

AstraZeneca (AZN)

AstraZeneca PLC

Von:

Regulatory News

Text Search:

Sortieren nach:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:AZN

<< Previous 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next >>

Datum	Zeit	Quelle	Überschrift	Symbol	Firma
06/06/2022	08h57	Dow Jones News	AstraZeneca Says Trial Shows Enhertu Reduced Risk of Breast Cancer Progression, Death by 50%	NASDAQ:AZN	AstraZeneca PLC
05/06/2022	14h10	Business Wire	ENHERTU® (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2-Low Metastatic Breast Cancer with HR-Positive and HR-Negative Disease	NASDAQ:AZN	AstraZeneca PLC
04/06/2022	16h00	Business Wire	CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line Chronic Lymphocytic Leukemia with 90% of Patients Surviving Five Years in ELEVATE-TN Trial	NASDAQ:AZN	AstraZeneca PLC
01/06/2022	16h19	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:AZN	AstraZeneca PLC
27/05/2022	15h00	Business Wire	First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis	NASDAQ:AZN	AstraZeneca PLC
23/05/2022	13h00	Business Wire	AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022	NASDAQ:AZN	AstraZeneca PLC
23/05/2022	09h03	Dow Jones News	AstraZeneca's Covid-19 Vaccine Gets EU Approval for Third Doses	NASDAQ:AZN	AstraZeneca PLC
20/05/2022	17h27	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:AZN	AstraZeneca PLC
16/05/2022	10h10	Dow Jones News	NetScientific Shares Rise on Successful Completion of AstraZeneca Covid-19 Antibody Test	NASDAQ:AZN	AstraZeneca PLC
15/05/2022	19h24	Business Wire	PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma	NASDAQ:AZN	AstraZeneca PLC
13/05/2022	22h21	PR Newswire (US)	Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination with Tagrisso® in Patients with Non-Small Cell Lung Cancer	NASDAQ:AZN	AstraZeneca PLC
12/05/2022	15h53	GlobeNewswire Inc.	Deutsche Bank’s Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing	NASDAQ:AZN	AstraZeneca PLC
12/05/2022	15h00	GlobeNewswire Inc.	AstraZeneca Joins Accumulus Synergy as a Sponsor to Accelerate the Delivery of Medicines to Patients	NASDAQ:AZN	AstraZeneca PLC
09/05/2022	15h25	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:AZN	AstraZeneca PLC
05/05/2022	14h58	GlobeNewswire Inc.	International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 10th and 11th, 2022	NASDAQ:AZN	AstraZeneca PLC
05/05/2022	13h05	Business Wire	FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction	NASDAQ:AZN	AstraZeneca PLC
05/05/2022	13h01	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:AZN	AstraZeneca PLC
05/05/2022	13h00	Business Wire	ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder	NASDAQ:AZN	AstraZeneca PLC
05/05/2022	13h00	Business Wire	ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen	NASDAQ:AZN	AstraZeneca PLC
05/05/2022	12h50	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:AZN	AstraZeneca PLC
05/05/2022	12h42	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:AZN	AstraZeneca PLC
05/05/2022	09h03	Dow Jones News	AstraZeneca's Enhertu Approved in US for Metastatic Breast Cancer Treatment	NASDAQ:AZN	AstraZeneca PLC
05/05/2022	08h57	Dow Jones News	AstraZeneca Says Farxiga Heart Treatment Phase 3 Trial Met Primary Endpoint	NASDAQ:AZN	AstraZeneca PLC
05/05/2022	08h52	Dow Jones News	AstraZeneca Says Autoimmune Disease Treatment Ultomiris Met Phase 3 Trial Primary Endpoint	NASDAQ:AZN	AstraZeneca PLC
04/05/2022	14h00	Business Wire	Imfinzi Plus Chemotherapy Granted Priority Review in the US for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial	NASDAQ:AZN	AstraZeneca PLC
04/05/2022	12h13	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:AZN	AstraZeneca PLC
04/05/2022	08h58	Dow Jones News	AstraZeneca's Imfinzi Combo Granted Priority Review Status in U.S.	NASDAQ:AZN	AstraZeneca PLC
03/05/2022	16h28	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:AZN	AstraZeneca PLC
29/04/2022	20h03	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:AZN	AstraZeneca PLC
29/04/2022	13h01	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:AZN	AstraZeneca PLC